Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

345
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
345
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

178
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
178
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

133
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
133
Actuarial Approach01:20

Actuarial Approach

77
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
77

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Examining Cost Differences in Malignant Brain and Central Nervous System Tumor Treatment Across US Military Health System Care Settings.

Journal of healthcare management / American College of Healthcare Executives·2026
Same author

Chronic inflammatory diseases and survival among patients with pancreatic cancer in the U.S. Military health system.

The American journal of medicine·2026
Same author

Can We Validate the Musculoskeletal Infection Society Criteria in Patients Suspected of Infection After Transfemoral Osseointegration Surgery?

Clinical orthopaedics and related research·2026
Same author

The Development of Tools to Investigate Potential Sources of Sample Misidentification Within a Biorepository: Case Studies.

Biopreservation and biobanking·2026
Same author

CORR Insights®: Is Functional Reconstruction Feasible With Modified Hip Transposition Using a Customized 3D-printed Femoral Prosthesis After Pelvic Tumor Resection? A Preliminary Study.

Clinical orthopaedics and related research·2026
Same author

Incidence of Hodgkin and Non-Hodgkin Lymphomas: Comparison of the Military and General Population.

Cancer medicine·2026

Related Experiment Video

Updated: Jun 27, 2025

Modeling Primary Bone Tumors and Bone Metastasis with Solid Tumor Graft Implantation into Bone
06:53

Modeling Primary Bone Tumors and Bone Metastasis with Solid Tumor Graft Implantation into Bone

Published on: September 9, 2020

2.7K

Bone Sarcoma Survival in the US Military Health System: Comparison With the SEER Program.

Ashley B Anderson1, Eungjae Kim, Amie B Park

  • 1From the Department of Surgery, Uniformed Services University of the Health Sciences and Walter Reed National Military Medical Center, Bethesda, MD (Anderson, Kim, Zhu, Lin, Shriver, and Potter), Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD (Park, Zhu, and Lin), John P. Murtha Cancer Center Research Program, Uniformed Services University of the Health Sciences and Walter Reed National Military Medical Center, Bethesda, MD (Zhu, Lin, and Shriver), and the Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD (Zhu and Lin).

The Journal of the American Academy of Orthopaedic Surgeons
|April 29, 2024
PubMed
Summary

Military health system patients with bone sarcoma show improved survival compared to the general population. This suggests universal access to high-quality care enhances bone sarcoma outcomes.

More Related Videos

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

259
Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models
04:25

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Published on: October 28, 2021

9.2K

Related Experiment Videos

Last Updated: Jun 27, 2025

Modeling Primary Bone Tumors and Bone Metastasis with Solid Tumor Graft Implantation into Bone
06:53

Modeling Primary Bone Tumors and Bone Metastasis with Solid Tumor Graft Implantation into Bone

Published on: September 9, 2020

2.7K
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

259
Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models
04:25

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Published on: October 28, 2021

9.2K

Area of Science:

  • Oncology
  • Health Services Research
  • Epidemiology

Background:

  • Access to healthcare is a critical determinant of cancer survival rates.
  • The US Military Health System (MHS) offers universal healthcare coverage to its beneficiaries.
  • The survival outcomes for bone sarcoma patients within the MHS compared to the general population remain understudied.

Purpose of the Study:

  • To compare the survival rates of bone sarcoma patients within the US Military Health System (MHS) against the general US population.
  • To investigate the impact of universal healthcare access on bone sarcoma patient survival.

Main Methods:

  • Utilized data from the Department of Defense Automated Central Tumor Registry (ACTUR) for MHS patients and the National Cancer Institute's SEER registry for the general population.
  • Included adult patients (≥25 years) with histologically confirmed bone sarcoma diagnosed between 1987 and 2013.
  • Employed Kaplan-Meier survival analysis and multivariable Cox proportional hazards models to compare overall survival between the two cohorts.

Main Results:

  • The study analyzed 2,273 bone sarcoma cases from ACTUR and 9,092 from SEER.
  • MHS patients demonstrated a significantly lower 5-year all-cause mortality risk (HR=0.72; 95% CI, 0.66-0.78) after adjusting for confounders.
  • Throughout the follow-up period, MHS patients exhibited a consistently lower risk of all-cause death compared to SEER patients (HR=0.75; 95% CI, 0.6-0.81).

Conclusions:

  • Beneficiaries of the MHS diagnosed with bone sarcoma may experience superior survival rates compared to patients in the general population.
  • These findings underscore the significant role of universal access to high-quality healthcare in improving outcomes for bone sarcoma patients.